Project Grant R01CA307595
Award Date 4/1/26
Completion Date 3/31/31
Dollars Obligated $680K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Houston, TX 77030, USA
Similar Awards
- Federal Project Grant Award Summary The University of Texas MD Anderson Cancer Center received a $421,685 project grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), awarded August 1, 2025, with a completion date of July 31, 2027. This award supports research investigating the LIFR-LCN2 pathway as a novel mechanism of immune suppression in hepatocellular carcinoma (HCC). The research aims to elucidate how loss of LIFR upregulates LCN2, leading to...
- Federal Grant Award Summary The National Cancer Institute awarded The University of Texas MD Anderson Cancer Center a $420,400 Project Grant under the Cancer Treatment Research program (CFDA 93.395) effective August 1, 2025, through July 31, 2027. This award supports exploratory studies investigating cellular resistance mechanisms to second-generation MTA-cooperative PRMT5 inhibitors (MTA:PRMT5I) in MTAP-loss tumors. The research addresses a critical clinical challenge whereby 40-60% of patients...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant of $616,715 to The University of Texas MD Anderson Cancer Center, with an award date of August 11, 2025 and completion date of July 31, 2030. This award supports research under the Cancer Treatment Research program (CFDA 93.395), which develops and evaluates improved methods of cancer treatment through fundamental and applied laboratory and clinical research. The funded research centers on the...
- Federal Grant Award Summary The University of Texas MD Anderson Cancer Center received a $163,500 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) on July 2, 2025, with completion scheduled for June 30, 2027. This award supports research aimed at developing targeted therapeutic approaches for E-cadherin-negative diffuse-type gastric adenocarcinoma (DGAC), an aggressive cancer subtype with increasing incidence rates and poor...
- Federal Grant Award Summary The National Cancer Institute awarded The University of Texas MD Anderson Cancer Center a $564,695 Project Grant under the Cancer Biology Research program (CFDA 93.396) on June 10, 2025, with a completion date of May 31, 2030. This award funds fundamental research investigating a newly discovered bone metastasis driver, acyl-CoA binding protein (ACBP), and its therapeutic potential in breast cancer. The research employs in vivo positive selection systems based on...
- Federal Project Grant Award Summary The University of Texas MD Anderson Cancer Center received a $510,671 Project Grant from the National Cancer Institute under the Cancer Cause and Prevention Research program (CFDA 93.393), awarded May 1, 2026, with a completion date of April 30, 2031. This award funds research into the functional characterization of lineage plasticity in cholangiocarcinoma (CCA), a highly aggressive bile duct cancer. The project will deliver a comprehensive functional...
- Federal Grant Award Summary The University of Texas MD Anderson Cancer Center received a $432,134 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) on June 5, 2025, with a completion date of May 31, 2027. This grant funds research into IL13RA2-targeted radioimmunotherapy (RIT) for glioblastoma, an aggressive primary brain tumor with poor prognosis. The research focuses on developing and evaluating therapeutic approaches that...
- Federal Grant Award Summary The University of Texas MD Anderson Cancer Center received a $1.85M Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), awarded September 19, 2025, with completion anticipated by August 31, 2029. The grant supports the clinical development and evaluation of next-generation CAR-NK (chimeric antigen receptor-engineered natural killer) cell therapies targeting CD5-positive T-cell malignancies. The research...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded MD Anderson Cancer Center a $2.46 million project grant under the Cancer Treatment Research program (CFDA 93.395) effective August 18, 2025, through July 31, 2030. The INHANCE (Imaging Innovation for Head and Neck Cancer Evaluation & Treatment Delivery) initiative develops advanced imaging and computational image analysis methodologies to predict, detect, prevent, and manage therapy-related normal tissue injury in head...
- Federal Grant Award Summary The University of Texas MD Anderson Cancer Center received a $449,625 Project Grant from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), awarded on September 15, 2025, with completion targeted for July 31, 2030. This award funds the development of novel statistical methods to delineate spatial and temporal patterns of cell-cell interactions (CCIs) in spatial transcriptomics (ST)...